智通财经APP讯，创美药业(02289)发布截至2024年12月31日止年度的全年业绩，营业总收入44.35亿元(人民币，下同)，同比增加0.72%;归母净利润5328.41万元，同比增加3.78%;基本每股收益0.4934元;拟派发末期股息每股0.45元。
公告称，营业收入增加主要由于(1)聚焦非招标市场，深化品牌合作：集团始终坚持在非招标市场的业务定位，并持续执行“深耕广东，辐射周边”的市场战略。这不仅提升了集团在品牌厂商中的认可度，也为集团赢得了更多优质产品的经销权和项目合作机会，为收入增长奠定了坚实基础;及(2)强化供应链优势，提升客户满意度：集团不断提升产品供应满足率，并持续优化供应链服务体系，这些优势得到了客户的广泛认可。高效、稳定的供应链服务不仅提升了客户满意度，也进一步增强了品牌影响力，为公司主营业务的稳健增长提供了有力支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.